To achieve its mission, the BRIMS Center collaborates with leading researchers and its parent organization, Thermo Fisher Scientific. These presentations document this work.
Development of Multiplexed Mass Spectrometric Immunoassay (MSIA)-SRM methods for proteins associated with alzheimer’s disease and application to clinical samples for research only (PDF 3.7 MB)
This presentation describes the development of novel multiplexed mass spectrometric immunoassay (MSIA) selected reaction monitoring (SRM) methods for the detection and quantification of Aβ and Apo E peptides in human cerebrospinal fluid and plasma.
Crystal: a new PD node for building high quality spectral libraries (PDF 3.39 MB)
BRIMS PD Users Meeting, October 23, 2013
Serendipity in the blood: Mass spectrometry in the discovery of clinical biomarkers (PDF 713 KB)
AFMR Symposium, Boston, 4/24/13 Mary F Lopez, Director BRIMS Biomarker Research Initiatives in Mass Spectrometry
California wine LC/MS analysis with SIEVE 2.0. (PDF 2.76 MB)
Michael Athanas, Ph.D. VAST SCIENTIFIC / BRIMS; Mark Dreyer, Ph.D. Thermo Fisher Scientific
Identification and quantification of in vitro peptide metabolites using a novel mass spectrometry-based workflow (PDF 2.77 MB)
Regular or decaf? Options for quantitative biomarker discovery (PDF 2.58 MB)
Conference Mass Spectrometry Applications in Clincal Laboratories, San Diego, Feb 2011
Novel MS discovery-to-targeted SRM workflows incorporating ROC curve analysis of putative biomarker candidates in bona fide clinical samples (PDF 3.41 MB)
Sweedish Proteomics Society, Gothenberg, Sweden, Nov 2010
Targeted SRM assays: creating a new clinical paradigm (PDF 1.9 MB)
AACC Conference. Washington D.C. 7/30/08